‘news’ Category

OMPI Results 1st Quarter 2008

Obagi Medical Products, Inc. (OMPI), a major player in the skin care systems arena this past week on May 5, 2008, reported financial results for the first quarter ended March 31, 2008.

CEO and OMPI President Steve Carlson stated, “This quarter’s performance was below our expectations as economic conditions prevented the Company from achieving targeted revenue and earnings growth. Most significantly, sales from our core Nu-Derm product line were down as a result of more cautious purchasing patterns, especially from our largest physician accounts that we believe service our most economically sensitive end-consumers. As has been our experience with other new product introductions, our decision to focus our sales and marketing resources on the introduction of ELASTIderm Decolletage System, which has been very well received, also impacted the performance of Nu-Derm during the quarter.

“While the current economic environment is unlikely to improve in the near term, our strong cash position, positive cash flow and debt-free capital structure makes Obagi Medical Products more competitively positioned than ever before. In light of these economic conditions, we have re-examined and re-aligned our expenditures for 2008 with our current growth expectations, while continuing to invest in product development, clinical support for our products, growth of our sales organization and other growth initiatives. We believe we will achieve double-digit revenue growth in 2008 through our active account growth, the development of our international business, further acceptance of the new ELASTIderm offering, and a new product launch planned for the fourth quarter.”

Obagi Medical Products shares drop bigtime

OMPI – Obagi Medical Products shares dropped to its lowest ever today closing at 6.86. Its highest stock price for this company was on November 6, 2007 where it was at 24.96.

Concerns over the performance of their 1st quarterly earnings report not meeting expectations could be a reason for the continued downfall of this stock.

How long will OMPI continue to drop? We’ll have to wait and see the upcoming earnings report, but my take is traders are heavily influencing and shorting the stock to go even further south.

Hang in there OMPI, your loyal customers love your products!

Obagi Products Timeline

Here’s a timeline that summarizes Obagi Medical Products, Inc. developments and products.

Obagi Medical Products formulates and markets skin health products for the dermatology, plastic and reconstructive surgery, and associated aesthetic markets.

Utilising its Penetrating Therapeutics(TM) technologies, Obagi Medical’s products are configured to improve penetration of agents across the skin barrier for common and obvious skin preconditions in adult skin including chloasma, melasma, senile lentigines, acne vulgaris and sun impairment.

The chronicle of Obagi’s skin care product entries is as follows:

  • 1988 – Obagi Nu-Derm
  • 2004 – Obagi-C Rx (the foremost and only prescription-strength vitamin C and hydroquinone system)
  • 2005 – Obagi Professional-C (a line of extremely balanced vitamin C serums)
  • 2006 – Obagi Nu-Derm Condition and Enhance for utilization with cosmetic routines to heighten patient results and
  • 2007 – Obagi ELASTIderm eye treatment and Obagi CLENZIderm M.D. acne therapeutic systems.
  • 2007 (JUNE) – Obagi CLENZIderm for normal to dry skin.

ObagiClear.net Launches!

A new website uniquely promoting Obagi Skin Care Products – Obagi Clear.net has just launched.

** Obagi Skin Care (WEBWIRE)– Sunday, January 27, 2008

ObagiClear.net aims to promote the complete line of Obagi Nu Derm skin care products including their basic Obagi System, Professional CRx, Elastiderm, and Clenziderm skin care line. Developed by Dr. Zein Obagi, the Obagi Nu Derm System synergistically helps to restore and rejuvenate healthy, beautiful skin.

One of their newest product, CLENZIderm M.D.™ is a prescription strength acne solution. Their official website (obagi.com) touts CLENZIderm as “the only acne treatment systems with a liquid form of benzoyl peroxide”, and “is clinically proven to provide visibly clearer skin as early as 2 weeks”

Obagi’s latest successful product out in the market is ELASTIderm™. Their website affirms “Obagi ELASTIderm uses a breakthrough bi-mineral complex to help replenish and crosslink elastin, and build collagen to give your skin functional elasticity”

Obagi’s clinical studies of ELASTIderm show:

* 46% – increase in elasticity in 9 weeks. Achieve youthful-looking skin fast.

* 16% – reduction in visible wrinkles after 9 weeks. Proven to reduce wrinkles in as little as two weeks.

* 71% – of subjects reported better results than achieved using other products. Uniquely effective results.

If you are looking for information and products on the Obagi Nu Derm Skin Care line, then visit ObagiClear.net. ObagiClear.net anticipates itself to be a one-stop resource for providing reviews, resources and information on Obagi. It will also educate consumers on skin conditions, skin ailments, other skin care products.